Do Wall Street Analysts Like Biogen Stock?

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $18.4 billion, the company’s products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

Shares of this leading biotechnology company have significantly underperformed the broader market over the past year. BIIB has declined 43.9% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 12.5%. In 2025, BIIB stock is down 15.4%, compared to the SPX’s 1.4% rise on a YTD basis.